• Price (USD)99.96
  • Today's Change0.45 / 0.45%
  • Shares traded759.90k
  • 1 Year change-22.48%
  • Beta1.6469
Data delayed at least 15 minutes, as of Oct 17 2019 19:28 BST.
More ▼

Profile data is unavailable for this security.

About the company

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • Revenue in USD (TTM)4.50bn
  • Net income in USD1.24bn
  • Incorporated1992
  • Employees2.66k
  • Location
    Alexion Pharmaceuticals Inc121 Seaport BlvdBOSTON 02210-2050United StatesUSA
  • Phone+1 (475) 230-2596
  • Fax+1 (203) 271-8198
  • Websitehttp://alexion.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ALXN:NSQ since
Achillion Pharmaceuticals IncAnnounced16 Oct 201916 Oct 2019Announced-4.63%1.23bn
Data delayed at least 15 minutes, as of Oct 17 2019 19:28 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
UCB SA5.19bn721.89m14.31bn7.50k19.131.9313.202.763.473.5224.9334.420.45251.835.20625,216.806.555.008.316.4973.9071.7014.4712.520.887110.100.17744.362.258.135.3257.39-0.1751.66
Merck KGaA17.00bn1.24bn15.17bn53.05k41.292.694.790.89232.577.9535.2540.370.40731.964.73296,888.603.014.544.015.9863.2766.097.3911.030.82536.130.39419.902.205.98-57.97-2.2814.485.64
Shionogi & Co Ltd3.26bn1.15bn17.41bn5.23k14.962.7913.155.34399.62399.621,129.652,144.110.47471.446.5767,728,260.0016.7713.2118.6715.0784.2877.7235.3226.766.21--0.001326.565.534.6521.9526.73-12.1115.36
Alexion Pharmaceuticals, Inc.4.50bn1.24bn22.31bn2.66k18.122.2013.644.965.495.9220.0245.330.32070.77764.551,693,901.008.833.249.533.5191.7290.4327.5310.963.5617.130.20650.0016.3421.64-95.69-39.1548.67--
Otsuka Holdings Co Ltd12.36bn794.13m22.55bn32.94k28.281.3815.681.82155.42155.422,481.393,174.690.52552.713.5340,831,550.003.52--4.29--66.75--6.71--1.95--0.1596--4.20---26.67------
Astellas Pharma Inc12.06bn2.08bn29.43bn16.24k14.362.5611.012.44117.97117.97684.09662.590.69141.973.7980,736,140.0011.9310.3415.6513.4377.7575.9017.2514.301.44--0.121737.460.46392.7634.9719.59-1.477.07
Data as of Oct 17 2019. Currency figures normalised to Alexion Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

49.43%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co.as of 30 Jun 201924.31m10.84%
The Vanguard Group, Inc.as of 30 Jun 201916.33m7.28%
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 201914.09m6.28%
BlackRock Fund Advisorsas of 30 Jun 201911.66m5.20%
SSgA Funds Management, Inc.as of 30 Jun 201911.10m4.95%
Jennison Associates LLCas of 30 Jun 20199.01m4.02%
Baker Bros. Advisors LPas of 30 Jun 20198.26m3.68%
ClearBridge Investments LLCas of 30 Jun 20196.01m2.68%
Columbia Management Investment Advisers LLCas of 30 Jun 20195.05m2.25%
Artisan Partners LPas of 30 Jun 20195.03m2.24%
More ▼
Data from 30 Jun 2019 - 30 Jun 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.